Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Factors Affecting Protein-Drug Binding: Drug Interactions

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimising and beta-testing a user-centred, accessible, self-management rehabilitation smartphone app (reCOVer) for long-COVID fatigue using qualitative interview methods.

Disability and rehabilitation·2025

Same author

Overall survival with abemaciclib in early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Late adverse ventricular remodelling as a consequence of acute left main coronary artery occlusion.

BMJ case reports·2025

Same author

Mode of Delivery and Subsequent Motor Function in Children With Myelomeningocele Without In Utero Repair.

Obstetrics and gynecology·2025

Same author

The use of indocyanine green for colorectal anastomoses: a systematic review and meta-analysis.

Annals of the Royal College of Surgeons of England·2024

Same author

Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy.

Pharmacological research·2023

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Interaction between statins and clopidogrel: is there anything clinically relevant?

R Bhindi¹, O Ormerod, J Newton

¹Institute of Cardiology, John Radcliffe Hospital, Oxford, UK.

QJM : Monthly Journal of the Association of Physicians

|August 5, 2008

Summary

Statins and thienopyridines are commonly used for cardiovascular conditions. While preclinical data suggest potential interactions, current clinical evidence does not support discontinuing their co-administration.

Related Experiment Videos

Last Updated: Jul 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Pharmacology
Cardiology
Drug Interactions

Background:

3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) are widely prescribed for hyperlipidemia and cardiovascular disease prevention.
Thienopyridines are increasingly used in coronary disease management for their antiplatelet effects, particularly in stable and unstable settings and post-percutaneous coronary intervention.
Concerns exist regarding potential interactions between statins and thienopyridines, especially those statins metabolized by cytochrome P3A4.

Purpose of the Study:

To evaluate the clinical significance of potential interactions between statins and thienopyridines.
To review existing preclinical and clinical data regarding the co-administration of these drug classes.

Main Methods:

Review of preclinical studies investigating drug-drug interactions.
Analysis of clinical trial data and observational studies on the co-administration of statins and thienopyridines.
Focus on statins metabolized by cytochrome P3A4 (e.g., atorvastatin, lovastatin, simvastatin) and clopidogrel.

Main Results:

Preclinical data suggest a potential interaction between certain statins (cytochrome P3A4 substrates) and clopidogrel.
No compelling clinical evidence currently exists to mandate the cessation of co-administration of statins and thienopyridines based on interaction concerns.

Conclusions:

Despite theoretical concerns based on preclinical data, the co-administration of statins and thienopyridines appears safe in clinical practice.
Further clinical investigation may be warranted, but current evidence does not support altering treatment regimens solely due to potential drug-drug interactions between these classes.